Quick Answer
Nurix Therapeutics, Inc. reported Total Revenue of $83.98 million for fiscal year 2025.
Nurix Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $83.98M +54.0% |
$54.55M -29.1% |
$76.99M +99.3% |
$38.63M +29.8% |
$29.75M +66.9% |
$17.82M -42.7% |
| Revenue (ASC 606) | $83.98M +54.0% |
$54.55M -29.1% |
$76.99M +99.3% |
$38.63M | — | — |
| Net Income | -$264.46M -36.6% |
-$193.57M -34.5% |
-$143.95M +20.2% |
-$180.36M -53.9% |
-$117.19M -171.0% |
-$43.24M -99.3% |
| Diluted EPS | -$3.05 -5.9% |
-$2.88 -8.7% |
-$2.65 +28.6% |
-$3.71 -35.9% |
-$2.73 | — |
| Total Assets | $688.13M +2.8% |
$669.34M +88.2% |
$355.60M -14.7% |
$416.76M -12.6% |
$476.77M +20.3% |
$396.34M +799.8% |
| Cash and Equivalents | $246.96M +124.5% |
$110.00M +101.4% |
$54.63M -15.3% |
$64.47M -19.9% |
$80.51M -32.5% |
$119.36M +242.8% |
| Stockholders Equity | $538.75M +2.2% |
$526.99M +162.8% |
$200.49M -34.0% |
$303.70M -11.3% |
$342.30M +17.9% |
$290.27M +602.9% |
| R&D Expense | $316.90M +43.0% |
$221.63M +17.2% |
$189.15M +2.5% |
$184.50M +58.5% |
$116.43M +75.1% |
$66.49M +47.7% |
| Operating Income | -$285.67M -34.1% |
-$213.03M -37.4% |
-$155.06M +15.7% |
-$183.87M -56.0% |
-$117.89M -81.4% |
-$64.98M -192.2% |
| Shares Outstanding | 101.81M +34.2% |
75.87M +55.7% |
48.72M +3.3% |
47.17M +5.6% |
44.66M +14.9% |
38.86M +981.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | August 31, 2025 | $7.89M | -37.3% | -82.1% |
| Revenue (ASC 606) | August 31, 2025 | $7.89M | -37.3% | -82.1% |
| Net Income | August 31, 2025 | -$86.42M | -76.5% | -98.8% |
| Diluted EPS | August 31, 2025 | -$1.03 | -53.7% | -98.1% |
| Total Assets | August 31, 2025 | $522.47M | +1.7% | -11.7% |
| Cash and Equivalents | August 31, 2025 | $78.44M | -20.8% | -6.9% |
| Stockholders Equity | August 31, 2025 | $372.25M | -1.2% | -16.8% |
| R&D Expense | August 31, 2025 | $86.12M | +55.2% | +10.3% |
| Operating Income | August 31, 2025 | -$91.39M | -67.3% | -89.1% |
| Shares Outstanding | August 31, 2025 | 76.87M | +14.6% | +0.6% |
- Nurix Therapeutics, Inc. reported Total Revenue of $83.98 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +54.0% in Total Revenue compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Revenue (ASC 606) of $83.98 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +54.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Net Income of -$264.46 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed a decrease of -36.6% in Net Income compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Diluted EPS of $3.05 per share (loss) for fiscal year 2025.
- Nurix Therapeutics, Inc. showed a decrease of -5.9% in Diluted EPS compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Total Assets of $688.13 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +2.8% in Total Assets compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Cash and Equivalents of $246.96 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +124.5% in Cash and Equivalents compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Stockholders Equity of $538.75 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +2.2% in Stockholders Equity compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported R&D Expense of $316.90 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +43.0% in R&D Expense compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Operating Income of -$285.67 million for fiscal year 2025.
- Nurix Therapeutics, Inc. showed a decrease of -34.1% in Operating Income compared to the prior fiscal year.
- Nurix Therapeutics, Inc. reported Shares Outstanding of 101.81 million shares for fiscal year 2025.
- Nurix Therapeutics, Inc. showed an increase of +34.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: